Investigating the mechanisms of drug sensitivity and resistance to targeted therapies for lung cancer.
How do tumor cells evolve during treatment? Can we slow or halt the evolution of acquired drug resistance?
Are all cells within a tumor created equal? Why are some cells killed by therapy while other are able to survive?
Why do targeted therapies stop working? Can we develop new therapies to overcome drug resistance?
Can we combine orthogonal targeted therapy and immunotherapy approaches to better fight lung cancer?
Therapy-induced APOBEC3A drives evolution of persistent cancer cells.
Our mission is to advance the development of new therapies for patients with lung cancer through scientific discovery of the molecular mechanisms of drug sensitivity and resistance, understanding tumor evolution during treatment, and identification of targetable vulnerabilities to guide investigation of novel therapeutic strategies.
We say farewell to Luke who will be attending the University of Utah in the Molecular Biology PhD program. Best wishes to you in your future endeavors – we will…Go to News
We say farewell to Sarah who will be starting as a research technician for lymphoma research in the Roth Lab at Weill Cornell Medicine. Best wishes to you in your…Go to News
We are privileged to partner with a number of individuals and organizations who support our research. We are grateful for their dedication to helping us in the fight against lung cancer.